Financials
Financial year 2025
Lira Pharma from Grobbendonk, company number BE0685498505, closed financial year 2025 with a result of € 210,951 after tax. For that financial year Lira Pharma recorded a gross margin of € 330,551 and equity of € 1.4 million. Compared with financial year 2024, the result moved from € 186,965 to € 210,951. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 18, 2026.
€ 1.4 million
▲ 17% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 210,951
▲ 13% vs 2024
Profit after tax over the fiscal year.
€ 71,640
▼ 17% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 1.4 million.
Debts at end 2025
€ 1.2 million
▼ 12% vs 2024
€ 150,886 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.
€ 1,454
▲ 5% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 44,580
▲ 19% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 334,144 | € 301,710 | € 301,341 | € 330,551 | ▲ 10% |
| Profit after taxes | € 213,076 | € 185,008 | € 186,965 | € 210,951 | ▲ 13% |
| Equity | € 854,934 | € 1,039,942 | € 1,226,906 | € 1,437,857 | ▲ 17% |
| Total debts | € 1,872,044 | € 1,712,704 | € 1,460,872 | € 1,286,981 | ▼ 12% |
| Cash | € 16,090 | € 97,820 | € 85,901 | € 71,640 | ▼ 17% |
| Retained profit | € 836,384 | € 1,021,392 | € 1,208,356 | € 1,419,307 | ▲ 17% |
| Bank debt | € 1,818,723 | € 1,675,202 | € 1,409,692 | € 1,235,528 | ▼ 12% |
| Balance sheet total | € 2,726,978 | € 2,752,646 | € 2,687,778 | € 2,724,838 | ▲ 1% |
Key figures of Lira Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Lira Pharma?
What happened at Lira Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 210,951 (▲ 13% vs 2024). filed late Source: NBB ↗
- New establishment in Grobbendonk. KBO
- Start of the company according to the CBE. KBO
- Raf Maria Louis Sempels became a director. NBB
- Linde Maria-Johanna Hugo Stegen became a director. NBB
In short
From € 213,076 profit in 2022 to € 210,951 profit in 2025.
Paid € 346,287 in corporate taxes since 2022.
Best year ever: 2022, with € 213,076 profit.
Management
Behind Lira Pharma are Raf Maria Louis Sempels and Linde Maria-Johanna Hugo Stegen. It owns 100% of Apotheek Stegen itself.
Directors
According to the 2025 annual accounts
Raf Maria Louis Sempels
Director
since 2017
Linde Maria-Johanna Hugo Stegen
Director
since 2017
Establishments
Establishment units
Physical locations of this company
Astridplein 70
2280 Grobbendonk
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0685.498.505
- VAT number
- BE 0685.498.505
- Registered office
- Astridplein 70, 2280 Grobbendonk
- Names & denominations
- Lira Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 30 November 2017
- Peppol
- Active · Active since 4 Dec 2025
- Activities · NACE
Activiteiten van holdings
Holdings